| abstract |
The present technology provides compounds, and compositions comprising such compounds, useful in the targeted radiotherapy of cancer and/or mammalian tissues overexpressing prostate-specific membrane antigen ("PSMA"), wherein the compounds are represented by the formula express or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M 1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed. |